

In re Application of:
Goggins and Ueki
Application No.: 10/084,555
Filed: February 25, 2002
Page 6

PATENT
ATTY. DOCKET NO.: JHU1700-1

REMARKS

By the present amendment, Applicants respectfully request incorporation of the attached Sequence Listing into the application. The specification has been amended to insert "SEQ ID NOS 106 through 114" into the Tables 3A and 3B on pages 53 and 54. SEQ ID NOS 106-114 are supported by the specification, as originally filed. Accordingly, no new matter has been added by the submission of the present amendments.

CONCLUSION

If the Examiner would like to discuss any of the issues raised in this Amendment or the attached sequence listing, Applicants' representative can be reached at (858) 677-1456.

Respectfully submitted,

Date: July 24, 2002


Lisa A. Haile, Ph.D.
Reg. No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

USPTO Customer Number: 28213

In re Application of:
 Goggins and Ueki
 Application No.: 10/084,555
 Filed: February 25, 2002
 Page 7

PATENT
 ATTY. DOCKET NO.: JHU1700-1

EXHIBIT A
MARKED-UP COPY SHOWING AMENDMENTS TO SPECIFICATION

In the Specification:

The Tables 3A and 3B on pages 53, 54, 55 have been amended as follows:

TABLE 3A

PRIMER SEQUENCE FOR BISULFITE-SEQUENCE

<u>Clone</u>	<u>Orientation</u>	<u>Sequence</u>	<u>Annealing Temperature</u>	<u>SEQ ID NO:</u>	
RAR β	Forward	5'-GAGTTGGTGTAGATTAG-3'	56	43	
	Reverse	5'-TTCCCAAAAAATCCAAATTC-3'		44	
	Sequence	5'-CTCCTTCAAATAACTTAC-3'		45	
THBS1	Forward	5'-AGAGAGGAGTTAGATTGG-3'	54	46	
	Reverse	5'-CAAAAAAACTAAAACCTAAC-3'		47	
CACNA1G	Forward Reverse Sequence	Forward primer			
		5'-		48	
		TGGATAAAGGATGTTGGGGTTG-		49	
		3' 5'-CCCTCCCCCTAACCCCTAAATCC-3'	55, 53, 51, 49*	50	
hMLH1	Forward Reverse Sequence	5'- 3' 5'-ACTCCCCCTCACTTTATTC-3'	58	51	
		ATTATTTAGTAGAGGTATATAAG-		52	
		3' 5'-CCAACCCCACCCCTAAC-3'			
		Forward primer			
MINT1	Forward Reverse Sequence	5'-AAGAGAGGGTGGAGAGTAG-3'	62	53	
		5'-		54	
		CCCCTAAAAAAAATCAAAATC-3'		55	
MINT2	Forward Reverse Sequence	5'- 3' 5'-TACACCAACTACCCAACTACCTC-	60, 58, 56, 54**	56	
		5'-ACTTCCATTAAAAACAACTAC-3'		57	
		5'-			
		YGTATGATTTTTGTTAGTTAAT		106	
MINT31	Forward Reverse Sequence	-3' 5'-	58		
		5'-TACACCAACTACCCAACTACCTC-			
		3' 5'-ACTTCCATTAAAAACAACTAC-3'			
MINT32	Forward Reverse Sequence	5'- 3' 5'-	58, 56, 54, 52***	58	
		TTTATTTATATAATTGTGTATGG-		59	
		3' 5'-CACCCCTCACTTACTAAAAC-3'			
		Reverse primer			
	Forward Reverse Sequence	5'-TTTGGGAGGTAAATTYGTGATT-		60	
		3'		61	
		5'-			
		ACCRAACAAAAACCTAAAAAAC-3'			
		3'			
		Forward primer			

* 55 (5 cycles), 53 (5 cycles), 51 (5 cycles), 49 (26 cycles)

** 60 (3 cycles), 58 (4 cycles), 56 (5 cycles), 54 (26 cycles)

*** 58 (3 cycles), 56 (4 cycles), 54 (5 cycles), 52 (26 cycles)

In re Application of:
 Goggins and Ueki
 Application No.: 10/084,555
 Filed: February 25, 2002
 Page 8

PATENT
 ATTY. DOCKET NO.: JHU1700-1

TABLE 3B-PRIMER SEQUENCES FOR MSP

<u>Clone</u>	<u>Orientation & Methylation</u>		<u>Sequence</u>	<u>Annealing Temperature</u>	<u>SEQ ID NO:</u>
P16	Unmethylated	F	5'-TTATTAGAGGGTGGGGATTGT-3'	60	62
		R	5'-CAACCCCAAACCCACAACCATAA-3'		107
	Methylated	F	5'-TTATTAGAGGGTGGGGCGGATCGC-3'	65	63
		R	5'-GACCCCCGAACCGCGACCTAA-3'		108
RAR β	Unmethylated	F	5'-AGGATTGGGATGTTGAGAATG-3'	58	64
		R	5'-TTACAAAAAACCTTCCAATACA-3'		109
	Methylated	F	5'-GGATTGGGATGTCGAGAAC-3'	64	65
		R	5'-TACAAAAAACCTTCCGAATACG-3'		110
CACNA1G	Unmethylated	F	5'-GTTTTTTTTGGATTTTGTGTTTG-3'	60	66
		R	5'-TTTATTCCAACCTCTCACTTCA-3'		111
	Methylated	F	5'-GTTTTTTCGGGGCGGTTTC-3'	62	67
		R	5'-TCCGACTTCTCGCTTCG-3''		112
TIMP-3	Unmethylated	F	5'-	59	68
		R	TTTGTGTTGTTATTGTTGTTGTTT		
	Methylated	F	-3	59	69
		R	5'-CCCCCCAAAAACCCACCTCA-3'		
THBS1	Unmethylated	F	5'-CGTTCGTTATTGTTGTTTCGGTTTC-		
		R	-3'		113
	Methylated	F	5'-CCGAAAACCCGCCTCG-3'		
		R			114
HMLH1	Unmethylated	F	5'-GTTGGTTGTTGTTATTGGTTG-3'	62	70
		R	5'-CCTAAACTCACAAACCAACTCA-3'		71
	Methylated	F	5'-TGCAGCGTTTTAAATGC-3'	62	72
		R	5'-TAAACTCGCAAACCAACTCG-3'		73
E-Cad	Unmethylated	F	5'-TTAATAGGAAGAGTGGATAGTG-3'	56	74
		R	5'-TCTATAAAATTACTAAATCTCTTC-3'		75
	Methylated	F	5'-TTAATAGGAAGAGCGGATAGC-3'	58	76
		R	3'-CTATAAAATTACTAAATCTCTTCG-3'		77
DAPK	Unmethylated	F	5'-TAATTTAGGTTAGAGGGTTATTGT-3'	53	78
		R	5'-CACAACCAATCAACAACACA-3'		79
	Methylated	F	5'-TTAGGTTAGAGGGTTATCGCGT-3'	57	80
		R	5'-TAACTAAAATTCACCTACCGAC-3'		81
MGMT	Unmethylated	F	5'-GGAGGATAGTTGGATTGAGTTAATGTT-	60	82
		R	3'		83
	Methylated	F	5'-CAAATCCCTCCCAAACACCAA-3'	60	84
		R	5'-GGATAGTCGGATCGAGTTAACGTC-3'		85
	Unmethylated	F	5'-CCCTCCCAAACGCCGA-3'		
		R			
	Methylated	F	5'-	59	86
		R	TTGTGTTTGTGTTGAGGTTTTGT-		87
	Methylated	F	3'	59	88
		R	5'-		89
	Methylated	F	AACTCCACACTCTCCAAAAACAAAACA-		
		R	3'		
	Methylated	F	5'-TTTCGACGTTCGTACCTTTCGC-3'		
		R	5'-GCACTTTCCGAAAACGAAACG-3'		

In re Application of:
Goggins and Ueki
Application No.: 10/084,555
Filed: February 25, 2002
Page 9

PATENT
ATTY. DOCKET NO.: JHU1700-1

MINT1	Unmethylated	F	5'-GGGGTTGAGGTTTTGTTAGT-3'	64	90	91
	Methylated	R	5'-TTCACAAACCTCAAATCTACTTCA-3'			
MINT2	Unmethylated	F	5'-GGGTGTTAAATGTAATAATTG-3'	58	94	95
	Methylated	R	5'-AAAAAAAACACCTAAAACCTCA-3'			
MINT31	Unmethylated	F	5'-GAATTGAGATGATTAAATTGGT-3'	64	98	99
	Methylated	R	5'-CTAAAACCATCACCCCTAAACA-3'			
MINT32	Unmethylated	F	5'-GAGTGGTAGAGGAATTAGGT-3'	62	102	103
	Methylated	R	5'-CTAAAAAACAAACAAACATCCA-3'			
		F	5'-GTGGTTAGAGGAATTAGGC-3'	64	104	105
		R	5'-AAACGAACGAAACGTCCG-3'			